全文获取类型
收费全文 | 1020809篇 |
免费 | 77368篇 |
国内免费 | 2701篇 |
专业分类
耳鼻咽喉 | 13141篇 |
儿科学 | 35110篇 |
妇产科学 | 29066篇 |
基础医学 | 148974篇 |
口腔科学 | 28163篇 |
临床医学 | 92737篇 |
内科学 | 198587篇 |
皮肤病学 | 23304篇 |
神经病学 | 81271篇 |
特种医学 | 39291篇 |
外国民族医学 | 305篇 |
外科学 | 152194篇 |
综合类 | 24077篇 |
现状与发展 | 1篇 |
一般理论 | 401篇 |
预防医学 | 80222篇 |
眼科学 | 22990篇 |
药学 | 73430篇 |
3篇 | |
中国医学 | 2076篇 |
肿瘤学 | 55535篇 |
出版年
2018年 | 11344篇 |
2017年 | 8783篇 |
2016年 | 9974篇 |
2015年 | 11191篇 |
2014年 | 15256篇 |
2013年 | 23057篇 |
2012年 | 30555篇 |
2011年 | 32499篇 |
2010年 | 19420篇 |
2009年 | 18198篇 |
2008年 | 29985篇 |
2007年 | 31737篇 |
2006年 | 32128篇 |
2005年 | 30730篇 |
2004年 | 29937篇 |
2003年 | 28717篇 |
2002年 | 27644篇 |
2001年 | 47298篇 |
2000年 | 48369篇 |
1999年 | 40628篇 |
1998年 | 11380篇 |
1997年 | 10272篇 |
1996年 | 10321篇 |
1995年 | 9960篇 |
1994年 | 9237篇 |
1993年 | 8620篇 |
1992年 | 32508篇 |
1991年 | 31730篇 |
1990年 | 31229篇 |
1989年 | 30094篇 |
1988年 | 27361篇 |
1987年 | 27544篇 |
1986年 | 25636篇 |
1985年 | 24825篇 |
1984年 | 18583篇 |
1983年 | 15667篇 |
1982年 | 9400篇 |
1981年 | 8472篇 |
1979年 | 16998篇 |
1978年 | 12316篇 |
1977年 | 10394篇 |
1976年 | 9841篇 |
1975年 | 10267篇 |
1974年 | 12416篇 |
1973年 | 11941篇 |
1972年 | 10965篇 |
1971年 | 10190篇 |
1970年 | 9455篇 |
1969年 | 8782篇 |
1968年 | 8164篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Emeline Colomba Patricia Pautier Fanny Pommeret Alexandra Leary 《Expert review of anticancer therapy》2019,19(6):437-446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
2.
3.
4.
Alexandra Katsimardou Konstantinos Imprialos Konstantinos Stavropoulos Alexandros Sachinidis Michalis Doumas 《Expert opinion on pharmacotherapy》2020,21(10):1241-1252
ABSTRACT
Introduction
Type 1 diabetes mellitus (T1DM) is a chronic, autoimmune disease that is characterized by total absence of insulin production. Hypertension is a common comorbidity in T1DM with complex pathophysiology, while it is also a well-recognized risk factor for the development of cardiovascular disease (CVD), as well as other microvascular diabetic complications. 相似文献5.
Stelter K. Theodoraki M. N. Becker S. Tsekmistrenko V. Olzowy B. Ledderose G. 《European archives of oto-rhino-laryngology》2015,272(3):639-639
European Archives of Oto-Rhino-Laryngology - 相似文献
6.
7.
8.
9.
Stephan Koter Tina U. Cohnert Korbinian B. Hindermayr Jörg Lindenmann Maximilian Brückner Wolfgang K. Oswald Georg Werkgartner Doris Wagner 《Journal of vascular surgery》2019,69(4):1227-1232
Objective
Low psoas muscle area is shown to be an indicator for worse postoperative outcome in patients undergoing vascular surgical. Additionally, it has been associated with longer durations of hospital stay in patients with cancer who undergo surgery and subsequently greater health care costs in Europe and the United States. We sought to evaluate this effect on hospital expenditure for patients undergoing vascular repair in a health care system with universal access.Methods
Skeletal muscle mass was assessed on preoperative abdominal computed tomography scans of patients undergoing open aortic aneurysm repair in a retrospective fashion. The skeletal muscle index (SMI) was used to define low muscle mass. Health care costs were obtained for all patients and the relationship between a low SMI and higher costs was explored using linear regression and cross-sectional analysis.Results
We included 156 patients (81.5% male) with a median age of 72 years undergoing elective surgery for infrarenal abdominal aortic aneurysm in this analysis. The median SMI for patients with low skeletal muscle mass was 53.21 cm2/kg and for patients without, 70.07 cm2/kg. Hospital duration of stay was 2 days longer in patients with low skeletal muscle mass as compared with patients with normal (14 days vs 11 days; P = .001), as was duration of intensive care stay (3 days vs 1 day; P = .01). The median overall hospital costs were €10,460 higher for patients with a low SMI as compared with patients with a normal physical constitution (€53,739 [interquartile range, €45,007-€62,471] vs €43,279 [interquartile range, €39,509-€47,049]; P = .001). After confounder adjustment, a low SMI was associated with a 14.68% cost increase in overall hospital costs, for a cost increase of €6521.Conclusions
Low skeletal muscle mass is independently associated with higher hospital as well as intensive care costs in patients undergoing elective aortic aneurysm repair. Strategies to reduce this risk factor are warranted for these patients. 相似文献10.
Emma J. Walker Noni E. MacDonald Nehal Islam Nicole Le Saux Karina A. Top Deshayne B. Fell 《Vaccine》2019,37(13):1725-1735